Wenzhou Kangning Hospital (2120) Fundamentals 2026 — P/E 8.3x, Revenue Analysis | SniperIQ
Wenzhou Kangning Hospital (2120) is a CN-listed Healthcare company in Medical - Care Facilities with a market capitalization of HK$507M, trading at HK$7.20 on the HKSE. This SniperIQ fundamentals page covers Wenzhou Kangning Hospital's valuation (P/E 8.3x, P/B 0.4x), profitability (net margin 3.4%), revenue (¥1.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Wenzhou Kangning Hospital's market cap?
Wenzhou Kangning Hospital (2120) has a market capitalization of approximately HK$507M, trading at HK$7.20 on the HKSE. Market cap moves with the live share price.
What is Wenzhou Kangning Hospital's P/E ratio?
Wenzhou Kangning Hospital's trailing twelve-month P/E ratio is 8.3x, with a price-to-book (P/B) of 0.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Wenzhou Kangning Hospital?
Wenzhou Kangning Hospital runs a net profit margin of 3.4%, a gross margin of 25.2%, and an operating margin of 5.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Wenzhou Kangning Hospital generate?
Wenzhou Kangning Hospital reported revenue of ¥1.6B for fiscal year 2025, with net income of ¥54M and earnings per share (EPS) of 0.76. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Wenzhou Kangning Hospital pay a dividend?
Wenzhou Kangning Hospital offers a trailing dividend yield of about 7.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Wenzhou Kangning Hospital financially healthy?
Wenzhou Kangning Hospital carries a debt-to-equity ratio of 0.99x and a current ratio of 1.31x, with a market beta of 0.18. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Wenzhou Kangning Hospital a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Wenzhou Kangning Hospital (2120) the key facts are: market cap HK$507M, P/E 8.3x, revenue ¥1.6B, 52-week range 7-11.7. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Wenzhou Kangning Hospital's full fundamentals live
Get Wenzhou Kangning Hospital's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.